Prescription medicine

Anacaulase-bcdb Brand names: Nexobrid

Anacaulase-bcdb (Nexobrid) is a prescription medicine with an FDA approval on record since 2022. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the anacaulase-bcdb FDA label on DailyMed (effective September 11, 2025, Vericel Corporation); the BLA 761192 record on Drugs@FDA; every anacaulase-bcdb label on DailyMed.

Highlights of the record

FDA label of September 11, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Forms and strengths

Kit.

On the market

Earliest approval on file: December 28, 2022 Nexobrid, Mediwound, Ltd; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded

What is anacaulase-bcdb used for?

From the label: indications and usage
NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. […]

Source: FDA drug label (NEXOBRID), BLA761192 (Mediwound, Ltd), as published by Vericel Corporation, effective September 11, 2025 (SPL set 1a2f23ad-78ef-43fa-9864-6bd77aac9e57), via openFDA; the full label on DailyMed

Is there a generic for anacaulase-bcdb (Nexobrid)?

No generic anacaulase-bcdb is approved (Drugs@FDA, October 8, 2026).

2022 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What next?

Check an interaction: what two or more labels say about each other